Akari Therapeutics, Plc (NASDAQ:AKTX) Short Interest Update

Akari Therapeutics, Plc (NASDAQ:AKTX) was the target of a significant drop in short interest during the month of April. As of April 15th, there was short interest totalling 600 shares, a drop of 94.3% from the March 31st total of 10,500 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 12,000 shares, the short-interest ratio is currently 0.1 days.

Akari Therapeutics Price Performance

Shares of NASDAQ AKTX opened at $1.18 on Friday. Akari Therapeutics has a twelve month low of $1.08 and a twelve month high of $5.50. The firm has a fifty day simple moving average of $1.77 and a 200 day simple moving average of $2.60.

Institutional Investors Weigh In On Akari Therapeutics

A hedge fund recently raised its stake in Akari Therapeutics stock. Omnia Family Wealth LLC boosted its stake in Akari Therapeutics, Plc (NASDAQ:AKTX) by 48.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 87,628 shares of the biopharmaceutical company’s stock after purchasing an additional 28,511 shares during the quarter. Omnia Family Wealth LLC owned about 1.55% of Akari Therapeutics worth $273,000 as of its most recent SEC filing. 5.06% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, StockNews.com started coverage on shares of Akari Therapeutics in a research note on Wednesday. They set a “sell” rating for the company.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.